CRO Equity Compensation Benchmarks: What to Expect by Stage

CRO base salary gets most of the attention. That's a mistake. At every company stage except enterprise public, the equity component of a CRO package is worth more than the base over a four-year window. Or it's worth nothing. The variance is enormous, and most CROs don't have the data to evaluate what they're being offered.

I track executive sales job postings weekly through The CRO Report. The dataset now covers 1,500+ postings. Most don't disclose equity in the posting itself. But combined with published benchmarks from Spencer Stuart, Carta data, and Pavilion's compensation surveys, we can build a clear picture of what CROs should expect.

This piece covers equity by company stage, the terms that matter more than the grant size, and the math you should run before signing anything.

CRO Equity by Company Stage

The following benchmarks represent typical CRO equity grants in 2026. These are fully diluted percentages for new hire grants, not total equity ownership over time.

Company Stage	Equity Range	Instrument	Avg CRO Base
Seed / Series A	0.50% - 1.50%	ISOs / NSOs	$193K-$257K
Series B	0.25% - 0.75%	ISOs / NSOs	$220K-$280K
Series C / D	0.15% - 0.50%	NSOs or RSUs	$268K-$335K
Late-Stage Private	0.10% - 0.30%	RSUs	$263K-$425K
Public Company	$200K-$500K/yr	RSUs	$199K-$264K

Two things stand out in this table. First, equity percentages shrink as base salary grows. That's expected: the company is more valuable, so a smaller percentage represents more absolute value. Second, public company CROs have the lowest base but the most predictable equity. The RSU grant has a known price, vests on a schedule, and can be sold immediately. No guessing about exits or liquidation preferences.

Seed and Series A: The High-Risk Bet

At Seed and Series A, a CRO equity grant of 0.5% to 1.5% is standard. Above 1.5% is rare and usually means you're the first go-to-market hire at a technical founding team. Below 0.5% is a red flag.

Here's the math that matters. Assume you're offered 1.0% at a company with a $20M post-money valuation after its Series A.

• Your 1.0% is worth $200,000 on paper at the current valuation
• If the company exits at $200M (10x), your 1.0% is worth $2,000,000 before dilution
• After Series B, C, and D dilution (assume 20% each round), your 1.0% becomes roughly 0.51%
• At a $200M exit, that's about $1,020,000. Minus your strike price. Minus taxes.

Now factor in probability. According to Carta's 2025 data, roughly 10% of Series A companies reach a $200M+ exit. So the expected value of that 1.0% grant is something like $100K (10% x $1M), spread over 4 years. That's $25K per year in expected equity value. Not nothing, but not the retirement-level number most people imagine when they hear "1% of a startup."

The base salary haircut at Seed/Series A is real. Our data shows $193K-$257K for CROs at this stage, compared to $268K-$335K at Series C/D. That's a $75K+ gap at the high end. Over four years, the base haircut costs you $300K+ in guaranteed cash. The equity has to cover that gap and then some, or the math doesn't work.

What to Negotiate at Seed/Series A

• Grant size: Push for the high end of the range (1.0-1.5%) if you're the first GTM hire
• Strike price: Ensure it's set at the 409A valuation, not a premium
• Exercise window: Ask for 5-10 years post-departure, not the standard 90 days
• Acceleration: Double-trigger acceleration on change of control is standard for CROs
• Refresh grants: Get a commitment to annual refresh grants in writing, not just verbally

Series B: The Transition Stage

Series B is where equity gets complicated. The company is too big for the early-employee-sized grants, but the exit path isn't clear enough for RSU-style compensation. CRO grants at Series B typically run 0.25% to 0.75%.

The trap at Series B: the 409A valuation has increased (often 3-5x from Series A), which means your options cost more to exercise. A 0.5% grant at a $100M valuation costs $500,000 to exercise. If you leave after two years (the average CRO tenure), you've vested 50% of your grant. Your exercise cost is $250,000. You have 90 days to come up with that cash, or you lose the options.

This is the single most important term in a Series B CRO offer: the post-termination exercise window. The standard 90-day window is a trap at this valuation level. If the company hasn't gone public or been acquired when you leave, you're betting $250K of your own money on a liquidity event that may be years away.

Companies that offer 5-10 year exercise windows are telling you they value their equity package honestly. Companies that stick to 90 days know that most departing employees won't exercise, which effectively reduces their dilution. It's a feature of the offer, not a bug. Recognize it.

Series C/D: RSUs Enter the Picture

At Series C and D, the equity conversation shifts. Options may still be offered, but RSUs become more common, especially at companies with a clear 18-36 month path to IPO.

The CRO equity grant at this stage is 0.15% to 0.50%. The base is higher ($268K-$335K), so the equity is a smaller percentage of total comp. But the absolute dollar value is often larger because the company is more valuable.

Running the numbers: 0.30% at a $500M valuation is $1.5M in paper value. At a $1B exit (2x), that's $3M before dilution. After one more round of dilution (assume 15%), roughly $2.55M. The expected value calculation is much more favorable here because Series C companies reach exit at a higher rate than Series A.

RSUs vs. Options at Series C/D

Factor	Stock Options	RSUs
Cost to You	Must pay strike price to exercise	Zero cost at vesting
Value if Stock Drops	Can go underwater (worthless)	Always has value (shares, not the right to buy shares)
Tax Timing	At exercise (ISOs) or sale (NSOs)	At vesting (taxed as income)
Upside in Growth	Higher (you captured the value from strike to sale)	Lower (you get the share at current value)
Risk	Higher (can lose exercise cost)	Lower (guaranteed value at vesting)

For CROs with families and mortgages (most of them at this level), RSUs are the safer instrument. You don't risk your own capital. The trade-off is less upside in a high-growth scenario. If the company 10x's from Series C, options would have been better. If the company 2x's, RSUs are better because you didn't risk $500K+ of your own money on a mediocre outcome.

Public Company: The Predictable Path

Public company CRO equity is the simplest: RSUs with a known price, liquid on vesting. Annual grants typically run $200K to $500K in RSU value for a CRO at a mid-to-large-cap company. Annual refresh grants based on performance can add another $100K-$300K per year.

The base salary at public companies is the lowest in our dataset ($199K-$264K). But total comp including RSUs puts public CROs at $400K-$764K+ per year, competitive with late-stage private companies where the equity is illiquid.

The advantage of public company equity: certainty. You know what the stock is worth. You can sell it on vesting. You can model your total comp accurately. The disadvantage: no 10x upside. A large-cap stock might appreciate 15-20% per year. That's wealth building, not life-changing money.

The Vesting Problem at 18-24 Months

Average CRO tenure is 18-24 months. Standard vesting is four years with a one-year cliff. Do the math.

If you leave at 18 months, you've vested approximately 37.5% of your grant. At 24 months, 50%. You're leaving 50-62.5% of your equity on the table. For a CRO with a 1.0% Seed-stage grant or a $400K public company RSU package, that's hundreds of thousands of dollars in unvested equity.

This vesting/tenure mismatch is one of the most expensive aspects of being a CRO. Some approaches to mitigate it:

• Front-loaded vesting: Some companies offer 40% in year one, 30% in year two, 20% in year three, 10% in year four. This rewards short tenure more favorably.
• Shorter vesting schedules: Three-year vesting (instead of four) with a six-month cliff. Less common but increasingly offered for C-level hires.
• Acceleration clauses: Double-trigger acceleration (termination within 12 months of a change of control) is standard. Single-trigger (acceleration on change of control regardless of employment status) is less common but more valuable.
• Signing bonus: A cash signing bonus that partially offsets the unvested equity from your previous role. This is standard for CRO hires and usually runs $50K-$200K.

What Job Postings Tell You About Equity

Most executive sales postings don't disclose equity. In our dataset of 1,500+ postings, fewer than 15% mention equity in any form. When they do, the language is usually vague: "equity compensation" or "stock options." Specific grant sizes are almost never posted.

What you can infer from the posting:

• "Competitive equity package" = They have equity but won't commit to a number until late in the process
• No mention of equity at all = Either there is no equity, or the company doesn't consider it a selling point. Both are concerning for a C-level role.
• "Stock options + base" = Early to mid-stage company, likely ISOs or NSOs
• "RSUs + base + bonus" = Late-stage or public company
• Specific dollar range for equity = Almost always a public company, where the annual RSU grant has a modeled value

If the posting doesn't mention equity, ask about it in the first conversation. Not the second. Not the third. The first. A CRO role without equity is a VP Sales role wearing a costume.

The Negotiation Playbook

At Seed/Series A: Negotiate Equity First

The base range is narrow ($193K-$257K) and there isn't much room to move it. The equity has more flexibility. Push for the high end of the range and focus on terms: exercise window, acceleration, refresh grants.

At Series B: Negotiate the Exercise Window

The grant size matters less than the exercise terms. A 0.75% grant with a 90-day exercise window is worth less than a 0.50% grant with a 10-year window, because you can actually afford to leave the company without losing your equity.

At Series C/D: Push for RSUs Over Options

If the company is offering options at Series C, ask why. The company may be trying to save dilution (RSUs are more expensive for the company because they always have value). But for you, RSUs are categorically better at this stage. The company is too expensive for the exercise cost to be reasonable.

At Public: Negotiate Refresh and Signing Bonus

The initial RSU grant is somewhat standardized. Where you have leverage: the annual refresh formula (performance-based vs. automatic) and the signing bonus to cover equity you're leaving at your current company. Get the signing bonus in writing with specific amounts, not "we'll make you whole."

How Recruiters and Search Firms Think About Equity

Executive search firms evaluate CRO candidates partly on their equity sophistication. A candidate who asks intelligent questions about equity (cap table position, dilution history, exercise window, 409A timing) signals that they've been through this before. A candidate who asks "how much equity?" without follow-up questions signals that they haven't.

For recruiters evaluating CRO packages: total comp modeling should include a range of exit scenarios. Don't present equity at face value. Show the candidate what 1.0% looks like at 2x, 5x, and 10x outcomes, net of dilution. Honest math builds trust. Inflated projections create resentful CROs 18 months later when reality doesn't match the pitch.